Eli Lilly and Co Newsroom

Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks

WSJNov 13 17:49 ET

Express News | Coatue Management: Change in Holdings Are as at Qtr-Ended Sept 30 Vs Qtr-Ended June 30

Reuters9minutes ago

Express News | Coatue Management Raises Share Stake in Eli Lilly by 19.8% to 247,900 Shares

Reuters13minutes ago

99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows

Benzinga50minutes ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector -- Barrons.com

Barron's13:53 ET

Global Increase in Diabetes Indicates More Room for GLP-1 Meds to Grow

Seeking Alpha11:46 ET

Thursday Market Chills From Election Celebration | Live Stock

Kevin Travers11:07 ET

Surging Diabetes Rate Underscores Vast Opportunity in Weight-loss Drugs

MarketWatchNov 14 06:57 ET

Eli Lilly and Co To Go Ex-Dividend On November 15th, 2024 With 1.3 USD Dividend Per Share

Moomoo NewsNov 13 20:00 ET

Express News | Lilly: Nearly 99% of Adults With Pre-Diabetes and Obesity or Overweight Treated With Tirzepatide Remained Diabetes-Free at 176 Weeks

ReutersNov 13 17:00 ET

Bitcoin Gets Closer to $100k Than Ever | Wall Street Today

Kevin TraversNov 13 16:36 ET

Top 10 Market-cap Stocks on Wall Street Ranked by SA Quant Metrics

Seeking AlphaNov 13 16:32 ET

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

BenzingaNov 13 13:59 ET

Bitcoin Breaks Above $90k, Market Flat Wednesday | Live Stock

Kevin TraversNov 13 11:24 ET

Eli Lilly Unusual Options Activity For November 13

BenzingaNov 13 10:00 ET

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board

BusinesswireNov 13 09:30 ET

Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price

BenzingaNov 13 09:24 ET

Treatment With Tirzepatide in Adults With Pre-diabetes and Obesity or Overweight Resulted in Sustained Weight Loss and Nearly 99% Remained Diabetes-free at 176 Weeks

Eli Lilly & Co.Nov 13 00:00 ET

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop

BenzingaNov 12 22:12 ET

Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal

BenzingaNov 12 17:41 ET